Profound Medical Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA74319B5027
CAD
9.31
0.76 (8.89%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Profound Medical Corp. stock-summary
stock-summary
Profound Medical Corp.
Pharmaceuticals & Biotechnology
Profound Medical Corp. is a commercial-stage medical device company. focused on customizable, incision-free therapies which combine real-time magnetic resonance imaging (MRI), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue. The Company’s products include TULSA-PRO System and SONALLEVE. The TULSA-PRO is used to ablate benign or malignant prostate tissue in patients with a variety of prostate diseases. Prostate diseases include prostate cancer and benign prostatic hyperlasia (BPH). Prostate cancer is one of the common types of cancer affecting men. TULSA-PRO and SONALLEVE share the common technological concept of using MRI to enable visualization of the surgeon desired tissue in real time. Both products also use thermal ultrasound technology to heat and ablate tissue.
Company Coordinates stock-summary
Company Details
2400 Skymark Ave Unit 6 , MISSISSAUGA ON : L4W 5K5
stock-summary
Tel: 1 647 47613501 647 8724849
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 6 Schemes (7.58%)

Foreign Institutions

Held by 72 Foreign Institutions (29.14%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Arun Menawat
Chairman of the Board, Chief Executive Officer
Ms. Murielle Lortie
Director
Mr. Brian Ellacott
Independent Director
Mr. Steve Forte
Independent Director
Mr. Kenneth Galbraith
Independent Director
Mr. Jean-Francois Pariseau
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Jun 2025)
Net Profit:
-22 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 231 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.78

stock-summary
Return on Equity

-106.03%

stock-summary
Price to Book

4.32